Promaxo MRI System for Prostate Biopsy
Prostate Cancer Diagnosis
ApprovedActive
Key Facts
About Promaxo
Promaxo is a private, commercial-stage medical device company pioneering in-office, interventional MRI for prostate cancer. Its core product is a compact, portable MRI system that allows urologists to perform MRI-guided biopsies and treatments within their own clinics, potentially increasing detection rates of clinically significant cancer. The company leverages AI and is developing robotic assistance to enhance precision. Promaxo's model targets the large prostate cancer diagnosis and treatment market by improving workflow for physicians and accessibility for patients.
View full company profileOther Prostate Cancer Diagnosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Triopsy Biopsy System | Triopsy | Commercial |
| OmnEcoil Device | OmnEcoil Instruments | Development/Prototype |
| QP-Prostate | Quibim | Commercial |